Thermogenic Composition for Obesity Treatment
Solution Overview
Problem
Current treatments for visceral fat accumulation and obesity-related conditions, such as insulin resistance and type 2 diabetes, have shown only marginal success, and there is a need for effective therapies that can promote thermogenesis and improve glucose uptake in peripheral tissues.
Innovation Solution
A thermogenic composition comprising molecules like epiregulin, IGFBP4, IGFBP7, GMFB, ephrin A5, ADAMT S9, and semaphorin 3E, which can be administered to induce thermogenesis, enhance innervation, and improve glucose uptake, potentially combined with biocompatible nanostructures for enhanced delivery.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments are used for visceral fat accumulation and obesity-related conditions, then treatment safety is maintained, but therapeutic efficacy is only marginal
Solution Approach 1:
The patent employs a composite therapeutic approach by combining multiple molecules (epiregulin, IGFBP4, IGFBP7, GMFB, ephrin A5, ADAMT S9, and semaphorin 3E) into a single composition. This composite strategy targets multiple pathways simultaneously - thermogenesis, innervation, and glucose uptake - thereby achieving synergistic therapeutic effects that overcome the marginal efficacy of conventional single-target treatments for visceral fat accumulation and obesity-related conditions
2Loss of energy
If thermogenesis is enhanced through molecular composition, then energy dissipation improves, but treatment complexity increases
Solution Approach 1:
The patent utilizes molecules with multi-functional capabilities that simultaneously perform multiple therapeutic functions. For example, the composition enhances thermogenesis (energy dissipation) while also improving glucose uptake and addressing insulin resistance. This multi-functionality allows a single composition to address multiple aspects of metabolic dysfunction without requiring separate treatments for each condition, thereby managing complexity while achieving comprehensive therapeutic effects
3Reliability
If glucose uptake is improved in peripheral tissues, then insulin resistance is reduced, but the mechanism complexity increases
Solution Approach 1:
The patent employs intermediary molecules (epiregulin, IGFBP4, IGFBP7, GMFB, ephrin A5, ADAMT S9, and semaphorin 3E) that act as mediators to improve glucose uptake in peripheral tissues. These molecules facilitate insulin signaling and glucose transport through complex molecular pathways, serving as intermediaries between insulin and its target tissues. This intermediary approach allows for improved insulin sensitivity through well-defined molecular mechanisms that can be targeted therapeutically
Data Source
AI summary
Thermogenic molecules and methods of using these molecules for treating or preventing a condition in a subject selected from the group consisting of visceral fat accumulation (e.g., Crohn's disease associated with visceral fat accumulation), obesity, diabetes, pre-diabetes, hypothermia, and chronic inflammation are disclosed. Also disclosed is a method for promoting glucose uptake in peripheral tissues (e.g., adipocytes and muscles) of a subject, enhancing nerve innervation in a subject, activating PI3 kinase in cell, and inducing leptin secretion by an adipocyte. Also disclosed are inhibitors of thermogenic molecules and methods of using these inhibitors to decrease thermogenesis of adipocytes in a subject. Also disclosed are self-assembled, biocompatible nanostructure non-covalently associated with a therapeutic or diagnostic peptide or peptidomimetic.